PHARMACEUTICAL 2011 - China Pharmaceutical R&D Summit

Website | Edit Freely

Category PHARMACEUTICAL 2011

Deadline: April 11, 2011 | Date: April 11, 2011-April 13, 2011

Venue/Country: Shanghai, China

Updated: 2011-03-08 10:30:26 (GMT+9)

Call For Papers - CFP

Understand the Regulatory Environment in China

Hear from a tuned-in Clinical CRO on the changing regulatory environment; a US company's insight on conducting global trials in Asia, and a leading consultant's strategy to bring Chinese drugs and biologics to US market.

Benefit from these Tried & Proven Clinical Strategies and Case Studies:

FIH Study in China: from IND Application to Study Completion

Getting Ready for Global Trials in China

Conducting Health Economics & Outcomes Research in China

Developing Risk Management Plan in Clinical Trials

Bridging China Data with Global Data - Global Simultaneous Development

Trials & Tribulations of Starting Clinical Trials in a New Geographic Region

Discovery to Preclinical Development & Partnerships

Hear the Latest in NCE Development from these Domestic Chinese Companies:

Hec Pharma, Ascentage Pharma, IMPACT Therapeutics, Sunwei Therapeutics, Argusina Shanghai, Nanjing Changao Pharmaceutical, Luye Pharma Group and TOT Shanghai

Get Exciting Partnering Strategies and Updates from:

Roche, Simcere Pharmaceuticals, Pfizer, AstraZeneca, Fosun Pharmaceutical, Synta Pharmaceuticals, DCB Taiwan, GSK and Eli Lilly

Biologics & Biosimilars Development

Hear Rarely-Told Stories of China's Biologics Development:

History of Licartin - a I-131 Labeled Anti-CD147 Launched in China for Liver Cancer

EGFR mAb - a 10-Year Development Effort

A 10-year Development History of Etanercept in China

TPO - an Innovative Biopharmaceutical Product in China

Interleukin-7 Receptor: A New Therapeutic Target Using Biological Approach

Developing Oral Insulin in China - Experiences and Lessons

Learn from Success Stories of Large Molecule Development from Around the World:

Alternatives to Antibodies - High Affinity Mirror-Image Oligonucleotides

Story of Abgenix: from XenoMouse to Panitumumab and Beyond

Development of Cell Therapy in China

Peptide Therapeutics in China

A never-before line-up of over 75 Speakers from international pharma, MNCs in China, and domestic Chinese pharma/biotechs will be sharing their expert opinions and experiences on clinical challenges, regulatory updates , NCE discovery efforts, preclinical partnerships, biosimilars development and more!

With shared Keynote and Plenary Sessions over 3 days, participants will be able to choose the conference of their choice or mix-and-match sessions from all 3 conferences, while taking advantage of the shared sessions and networking breaks to meet with other executives and scientists at the event.

With proven attendance from top-level executives from China's major pharma and biotech companies, this is THE MEETING PLACE to network and share experiences, meet potential partners and foster business relationships.